Read by QxMD icon Read


Eva Oppel, Christof Högg, Burkhard Summer, Franziska Ruëff, Franz-Xaver Reichl, Stefanie Kamann
No abstract text is available yet for this article.
May 15, 2018: Contact Dermatitis
Thomas Danne, Anke Schwandt, Torben Biester, Bettina Heidtmann, Birgit Rami-Merhar, Holger Haberland, Silvia Müther, Semik Khodaverdi, Thomas Haak, Reinhard W Holl
OBJECTIVE: To examine glycemic control in youth with type 1 diabetes (T1D) who switched from multiple daily injections (MDI) to a tubeless insulin pump (Omnipod Insulin Management System, Insulet Corporation, Billerica, Massachusetts) compared to patients who continued MDI therapy over a 3-year time period. RESEARCH DESIGN AND METHODS: This retrospective analysis of the German/Austrian Diabetes Patienten Verlaufsdokumentation registry included data from 263 centers and 2529 patients <20 years (n = 660 tubeless insulin pump; n = 1869 MDI) who initiated treatment on a tubeless insulin pump as of January 1, 2013 and had 1 year of data preswitch from MDI and 3 years of data postswitch to a tubeless pump...
February 15, 2018: Pediatric Diabetes
Bruce A Buckingham, Gregory P Forlenza, Jordan E Pinsker, Mark P Christiansen, R Paul Wadwa, Jennifer Schneider, Thomas A Peyser, Eyal Dassau, Joon Bok Lee, Jason O'Connor, Jennifer E Layne, Trang T Ly
BACKGROUND: The safety and feasibility of the OmniPod personalized model predictive control (MPC) algorithm in adult, adolescent, and pediatric patients with type 1 diabetes were investigated. METHODS: This multicenter, observational trial included a 1-week outpatient sensor-augmented pump open-loop phase and a 36-h inpatient hybrid closed-loop (HCL) phase with announced meals ranging from 30 to 90 g of carbohydrates and limited physical activity. Patients aged 6-65 years with HbA1c between 6...
April 2018: Diabetes Technology & Therapeutics
Alejandro J Laguna Sanz, Christopher M Mulla, Kristen M Fowler, Emilie Cloutier, Allison B Goldfine, Brett Newswanger, Martin Cummins, Sunil Deshpande, Steven J Prestrelski, Poul Strange, Howard Zisser, Francis J Doyle, Eyal Dassau, Mary-Elizabeth Patti
BACKGROUND: Postbariatric hypoglycemia (PBH) is a complication of bariatric surgery with limited therapeutic options. We developed an event-based system to predict and detect hypoglycemia based on continuous glucose monitor (CGM) data and recommend delivery of minidose liquid glucagon. METHODS: We performed an iterative development clinical study employing a novel glucagon delivery system: a Dexcom CGM connected to a Windows tablet running a hypoglycemia prediction algorithm and an Omnipod pump filled with an investigational stable liquid glucagon formulation...
February 2018: Diabetes Technology & Therapeutics
L Leelarathna, S A Roberts, A Hindle, K Markakis, T Alam, A Chapman, J Morris, A Urwin, P Jinadev, M K Rutter
AIMS: To compare long-term HbA1c changes associated with different insulin pumps during routine care in a large cohort of adults with Type 1 diabetes representative of other clinic populations. METHODS: Observational, retrospective study of 508 individuals starting pump therapy between 1999 and 2014 (mean age, 40 years; 55% women; diabetes duration, 20 years; 94% Type 1 diabetes; median follow-up, 3.7 years). Mixed linear models compared covariate-adjusted HbA1c changes associated with different pump makes...
October 2017: Diabetic Medicine: a Journal of the British Diabetic Association
William H Polonsky, Danielle Hessler, Jennifer E Layne, Howard Zisser
BACKGROUND: Few recent studies have examined the impact of continuous subcutaneous insulin infusion systems on patient-reported quality of life (QOL). We explored QOL changes resulting from treatment with the Omnipod® Insulin Management System (Insulet Corp., Billerica, MA). METHODS: One thousand two hundred forty-five adults (>18 years) with type 1 diabetes and current Omnipod users completed an online questionnaire examining perceived changes in QOL and glycemic control since Omnipod initiation...
October 2016: Diabetes Technology & Therapeutics
Dario Pitocco, Alessandro Rizzi, Annalisa Tortora, Andrea Manto, Francesco Zaccardi, Giovanni Ghirlanda, Guido Costamagna, Maria Elena Riccioni
Video capsule endoscopy (VCE) is a noninvasive diagnostic tool used to observe the small intestinal mucosa. We report a case of a 57-year-old woman with T2DM, treated with continuous subcutaneous insulin infusion using second-generation OmniPod patch pump, undergoing VCE (Given M2A; VCE Ltd, Yoqneam, Israel) for melena and anemia. During VCE, an abnormal interruption of communication between video capsule and its receiver occurred. Two hours after capsule ingestion, the patient activated the insulin pump infusion through the Personal Diabetes Manager (PDM) because she drank a sugary beverage for the first time after ingestion...
July 2016: Diabetes Technology & Therapeutics
Jessica R Castle, Joseph El Youssef, Deborah Branigan, Brett Newswanger, Poul Strange, Martin Cummins, Leon Shi, Steven Prestrelski
BACKGROUND: There is currently no stable liquid form of glucagon commercially available. The aim of this study is to assess the speed of absorption and onset of action of G-Pump™ glucagon at 3 doses as compared to GlucaGen®, all delivered subcutaneously via an OmniPod®. METHODS: Nineteen adult subjects with type 1 diabetes participated in this Phase 2, randomized, double-blind, cross-over, pharmacokinetic/pharmacodynamic study. Subjects were given 0.3, 1.2, and 2...
September 2016: Journal of Diabetes Science and Technology
Jennifer E Layne, Christopher G Parkin, Howard Zisser
BACKGROUND: Continuous subcutaneous insulin infusion (CSII) treatment with a tubeless patch pump has not been previously evaluated in a large cohort of patients. METHODS: This multisite, retrospective study evaluated glycemic control in patients with type 1 diabetes (n = 873) after 3 months treatment the Omnipod(®) insulin management system (Insulet Corporation, Billerica, MA) compared to prior treatment with multiple daily injections (MDI) (78.1%) or CSII (21...
September 2016: Journal of Diabetes Science and Technology
Brett Newswanger, Steve Ammons, Neelima Phadnis, W Kenneth Ward, Jessica Castle, Robert W Campbell, Steven J Prestrelski
Despite a vigorous research effort, to date, the development of systems that achieve glucagon stability in aqueous formulations (without reconstitution) has failed to produce any clinical candidates. We have developed a novel, nonaqueous glucagon formulation based on a biocompatible pharmaceutical solvent, dimethyl sulfoxide, which demonstrates excellent physical and chemical stability at relatively high concentrations and at high temperatures. This article reports the development of a novel, biocompatible, nonaqueous native human glucagon formulation for potential use in subcutaneous infusion pump systems...
January 2015: Journal of Diabetes Science and Technology
Fraser Cameron, Günter Niemeyer, Darrell M Wilson, B Wayne Bequette, Kari S Benassi, Paula Clinton, Bruce A Buckingham
BACKGROUND: Closed-loop control of blood glucose levels in people with type 1 diabetes offers the potential to reduce the incidence of diabetes complications and reduce the patients' burden, particularly if meals do not need to be announced. We therefore tested a closed-loop algorithm that does not require meal announcement. MATERIALS AND METHODS: A multiple model probabilistic predictive controller (MMPPC) was assessed on four patients, revised to improve performance, and then assessed on six additional patients...
November 2014: Diabetes Technology & Therapeutics
Sophie Borot, Sylvia Franc, Justine Cristante, Alfred Penfornis, Pierre-Yves Benhamou, Bruno Guerci, Hélène Hanaire, Eric Renard, Yves Reznik, Chantal Simon, Guillaume Charpentier
The JewelPUMP™ (JP) is a new patch pump based on a microelectromechanical system that operates without any plunger. The study aimed to evaluate the infusion accuracy of the JP in vitro and in vivo. For the in vitro studies, commercially available pumps meeting the ISO standard were compared to the JP: the MiniMed® Paradigm® 712 (MP), Accu-Chek® Combo (AC), OmniPod® (OP), Animas® Vibe™ (AN). Pump accuracy was measured over 24 hours using a continuous microweighing method, at 0.1 and 1 IU/h basal rates...
November 2014: Journal of Diabetes Science and Technology
Luis G Jahn, Jorge J Capurro, Brian L Levy
BACKGROUND: As all major insulin pump manufacturers comply with the international infusion pump standard EN 60601-2-24:1998, there may be a general assumption that all pumps are equal in insulin-delivery accuracy. This research investigates single-dose and averaged-dose accuracy of incremental basal deliveries for one patch model and three durable models of insulin pumps. METHOD: For each pump model, discrete single doses delivered during 0.5 U/h basal rate infusion over a 20 h period were measured using a time-stamped microgravimetric system...
July 1, 2013: Journal of Diabetes Science and Technology
Boris P Kovatchev, Eric Renard, Claudio Cobelli, Howard C Zisser, Patrick Keith-Hynes, Stacey M Anderson, Sue A Brown, Daniel R Chernavvsky, Marc D Breton, Anne Farret, Marie-Josée Pelletier, Jérôme Place, Daniela Bruttomesso, Simone Del Favero, Roberto Visentin, Alessio Filippi, Rachele Scotton, Angelo Avogaro, Francis J Doyle
OBJECTIVE: To evaluate the feasibility of a wearable artificial pancreas system, the Diabetes Assistant (DiAs), which uses a smart phone as a closed-loop control platform. RESEARCH DESIGN AND METHODS: Twenty patients with type 1 diabetes were enrolled at the Universities of Padova, Montpellier, and Virginia and at Sansum Diabetes Research Institute. Each trial continued for 42 h. The United States studies were conducted entirely in outpatient setting (e.g., hotel or guest house); studies in Italy and France were hybrid hospital-hotel admissions...
July 2013: Diabetes Care
Yoeri M Luijf, Sabine Arnolds, Angelo Avogaro, Carsten Benesch, Daniela Bruttomesso, Anne Farret, Lutz Heinemann, Jerome Place, Eric Renard, Rachele Scotton, J Hans DeVries
BACKGROUND AND AIMS: The aim of this study was to compare blood glucose and plasma insulin profiles after bolus insulin infusion by a patch pump (PP) versus a conventional pump (CP), directly after placement and after Day 3 of use. PATIENTS AND METHODS: Twenty patients with type 1 diabetes came in for two blocks of visits: one block of two visits while wearing the OmniPod® (Insulet Corp., Bedford, MA) insulin pump (PP) and one block of two visits while wearing the Medtronic Diabetes (Northridge, CA) Paradigm® pump (CP)...
July 2013: Diabetes Technology & Therapeutics
Yael Lebenthal, Liora Lazar, Hadassa Benzaquen, Shlomit Shalitin, Moshe Phillip
AIMS: This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: Twenty-nine patients (age, 24.0 ± 5.1 years; diabetes duration, 12.1 ± 5.7 years; insulin pump duration, 6.4 ± 3.1 years; glycated hemoglobin [HbA1c], 8.6 ± 0.7%) participated in a randomized, two-arm open crossover study comparing two consecutive 12-week periods of continuous subcutaneous insulin infusion (CSII): one period using the OmniPod system and the other period using conventional CSII...
May 2012: Diabetes Technology & Therapeutics
Manuel Ochoa, Babak Ziaie
In this issue of Journal of Diabetes Science and Technology, Zisser and collegues describe two inexpensive methods for accurate measurement of dosage delivered by OmniPod insulin pump. The first method is based on imaging a meniscus movement in a micro-pipette and using simple image analysis; the second relies on using a digital microscope to measure the volume of a dispensed droplet while it is still attached to the cannula tip. Both methods produce accurate measurements for doses >0.2 U, and the latter method is especially appropriate for doses <0...
November 1, 2011: Journal of Diabetes Science and Technology
Howard Zisser, Marc Breton, Eyal Dassau, Kateryna Markova, Wendy Bevier, Dale Seborg, Boris Kovatchev
BACKGROUND: This article describes two novel and easy approaches for assessing the accuracy of insulin pumps as implemented within the artificial pancreas system. The approaches are illustrated by data testing the OmniPod Insulin Management System at its lowest delivery volume (0.05 U) and at doses of 0.1, 0.2, 1, and 6U. METHOD: In method 1, a pipette, digital microscope, and imaging software were used to measure average bolus delivery on a linear scale for multiple volumes...
November 1, 2011: Journal of Diabetes Science and Technology
Howard C Zisser
This review of insulin pump therapy focuses on the OmniPod® Insulin Management System (Insulet Corp., Bedford, MA, USA). The OmniPod System is the first commercially available "patch pump." It is a fully integrated wearable pump, controlled wirelessly through a handheld device containing a built-in blood glucose meter. This is an evaluation of the OmniPod System, with the aim of providing an educational tool for physicians who are considering recommending this product to their patients. The review includes a discussion of the traditional insulin pump configuration and its limitations, a detailed overview of the OmniPod System, references to clinical study data, planned product enhancements, its use as an insulin delivery system in the Juvenile Diabetes Research Foundation's Artificial Pancreas Project, and its use to deliver additional compounds...
August 2010: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Andreas Pfützner, Petra B Musholt, Bjoern Malmgren-Hansen, Nils H Nilsson, Thomas Forst
Insulin pump therapy [continuous subcutaneous insulin infusion (CSII)] requires regular change of infusion sets every 2-3 days in order to minimize the risk of skin irritations or other adverse events. This has been discussed to be a potential burden to the environment. The purpose of this analysis was to perform an environmental assessment of insulin pump infusion sets based on loss of resources occurring during incineration of the discarded products and by means of a lifecycle concept used to weight a material in relation to its rareness on earth and its consumption...
July 1, 2011: Journal of Diabetes Science and Technology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"